HR0138LRB102 17334 MST 22824 r


  
1
HOUSE RESOLUTION

  
 
2    WHEREAS, Precision medicine, which is also called 
3personalized health care or individualized medicine, is an 
4evolving field in which healthcare providers use analysis of a 
5patient's biospecimen, known as biomarker testing, to 
6determine which medical treatments will work best for each 
7patient; and
  
 
8    WHEREAS, By combining the data from biomarker testing with 
9an individual's medical history, circumstances, and values, 
10healthcare providers can direct a patient to targeted 
11treatment, which benefits both patients and the overall 
12healthcare system; and
  
 
13    WHEREAS, The field of precision medicine holds great 
14promise in ensuring the delivery of the right treatment to the 
15right patient at the right time; and
  
 
16    WHEREAS, Sixty percent of treatments in preclinical 
17development rely on biomarker data; and
 
18    WHEREAS, Biomedicine and the understanding of the 
19characteristics of a patient's disease that informs precision 
20medicine is evolving rapidly; and
 
 
 
HR0138- 2 -LRB102 17334 MST 22824 r

1    WHEREAS, Healthcare providers are increasingly gaining 
2access to new technologies, such as biomarker testing, that 
3can help identify gene mutations, alterations, or protein 
4expressions specific to individual patients; and
 
5    WHEREAS, Health outcomes are improved through the use of 
6precision medicine; for example, patients with certain types 
7of lung cancer who received biomarker testing had a 28 percent 
8reduction in mortality; and
 
9    WHEREAS, The National Academy of Medicine considers 
10biomarker tests to be "key to unlocking the promise" of 
11personalized health care; and
 
12    WHEREAS, Biomarker testing is available for an 
13ever-increasing range of conditions and diseases, but patient 
14access to these tests is not keeping pace with the rate of 
15innovation; and
 
16    WHEREAS, A lack of awareness among providers and patients, 
17a lack of common terminology, and deficient coverage policies 
18by both public and private payers are preventing effective 
19adoption and integration of biomarker testing into precision 
20medicine and appropriate awareness and education about the 
21ways biomarker testing can be used to support diagnosis, 
22treatment, and monitoring of patients in a personalized way; 
 
 
HR0138- 3 -LRB102 17334 MST 22824 r

1and

  
 
2    WHEREAS, The Illinois Department of Public Health and 
3other relevant partners seek to promote awareness, education, 
4and action related to improving access to biomarker testing; 
5therefore, be it
  
 
6    RESOLVED, BY THE HOUSE OF REPRESENTATIVES OF THE ONE 
7HUNDRED SECOND GENERAL ASSEMBLY OF THE STATE OF ILLINOIS, that 
8we declare March 2021 as "Precision Medicine and Biomarker 
9Testing Awareness Month" to raise awareness, encourage 
10education, and improve understanding of the ways biomarker 
11testing can be used to support diagnosis, treatment, and 
12monitoring of patients in a personalized way and the 
13importance of ensuring access to these promising technologies.